MarketPR
Silexion Therapeutics Corp (NASDAQ: SLXN) entered into an inducement offer letter on September 28, 2026, to reduce the exercise price of 3,216,928 existing Series E warrants from $0.65 to $0.2603 per share.
The company expects to receive approximately $0.84 million in gross proceeds from the cash exercise of these warrants, before deducting placement agent fees and other offering expenses.
The inducement agreement was reached with holders of the existing warrants, which were issued during a public offering completed on August 11, 2026.
In exchange for the reduced exercise price, the holders agreed to exercise their warrants for cash. Silexion agreed to issue new ordinary share purchase warrants, known as New Warrants, to the holders.
Keep reading